Celgene Corp., a long-time backer of privately held Triphase Accelerator Corp., has acquired the company's ocean-sourced proteasome inhibitor, marizomib, currently in development for the I.V. treatment of glioblastoma and relapsed/refractory multiple myeloma, the home territory of Celgene's Revlimid (lenalidomide).